Clene Nanomedicine
Salt Lake City, US · Delaware corporation · 1 known investors
Find your way into Clene Nanomedicine
387 people in our graph share verified history with the Clene Nanomedicine team — schools, employers, funds. One of them is your warm intro.
Michael Lintsunlockedknows Rob Etherington · together at Harvard Business School (overlapped)
×11knows the team · via Harvard Business School
Founders & leadership
RE
Rob EtheringtoninCEO/PresidentRob Etherington is Founding President and CEO of Clene Nanomedicine, a clinical-stage biopharmaceutical company developing CNM-Au8 for neurodegenerative diseases. He brings over 30 years of experience in biopharma drug development and executive roles at global pharmaceutical and biotech companies, and has led Clene through its 2021 Nasdaq public listing.
RL
Ryan LundNamed on SEC filing
JS
John StevensNamed on SEC filing
DL
David LisonbeeNamed on SEC filing
CY
Chad YoungNamed on SEC filing
RW
Reed WilcoxNamed on SEC filing
SJ
Shalom JacobovitzNamed on SEC filing
AM
Alison MoscaNamed on SEC filing
RG
Robert GayNamed on SEC filing
Investors · 1
Also in the syndicate · 1
SymBiosis II, LLClead
Reported raises · per SEC filings
Form D private placements$48.7M disclosed across 2 rounds · 2020
▶$42.5MraisedAug 2020 · 61 investors · PharmaceuticalsRule 506(b)
▶$42.5MraisedAug 2020 · 61 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shalom JacobovitzDirector
- Alison MoscaDirector
- Chad YoungDirector
- Reed WilcoxDirector
- David LisonbeeDirector
- John StevensDirector
- Robert GayDirector
- Rob EtheringtonExecutive Officer, Director
- Offering amount
- $46.2M
- Amount sold
- $42.5M
- Minimum investment
- $10K
- Sales commissions
- $949.1K
- Placement agents
- Crewe Capital, LLC
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJul 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$6.1MraisedJul 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ryan LundDirector
- John StevensDirector
- Rob EtheringtonExecutive Officer, Director
- David LisonbeeDirector
- Chad YoungDirector
- Reed WilcoxDirector
- Shalom JacobovitzDirector
- Alison MoscaDirector
- Robert GayDirector
- Offering amount
- $7M
- Amount sold
- $6.1M
- Minimum investment
- $25K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Clene Announces $4 Million Registered Direct Offering - BioSpacebiospace.com · Sep 2026Clene to Present at Upcoming September 2026 Investor Conferences - BioSpacebiospace.com · Sep 2026Frequently asked questions
- How much funding has Clene Nanomedicine raised?
- Clene Nanomedicine has disclosed $48.7M raised across 2 rounds.
- Where is Clene Nanomedicine headquartered?
- Clene Nanomedicine is headquartered in Salt Lake City, US.